Zai Lab Overview
- Year Founded
-
2014
- Status
-
Public
- Employees
-
2,175
- Stock Symbol
-
09688
- Investments
-
2
- Share Price
-
$3.09
- (As of Monday Closing)
Zai Lab General Information
Description
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
Contact Information
Website
www.zailaboratory.comCorporate Office
- Building 1, 4 Floor, Jinchuang Plaza
- 4560 Jinke Road, Pudong
- Shanghai, 201210
- China
Corporate Office
- Building 1, 4 Floor, Jinchuang Plaza
- 4560 Jinke Road, Pudong
- Shanghai, 201210
- China
Zai Lab Stock Performance
(As of Monday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$3.09 | $3.02 | $1.35 - $3.32 | $3.07B | 996M | 3.85M | -$0.31 |
Zai Lab Financials Summary
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
---|---|---|---|---|
EV | 1,113,373 | 1,903,072 | 1,991,307 | 4,704,230 |
Revenue | 322,711 | 266,719 | 215,040 | 144,312 |
EBITDA | (325,858) | (365,388) | (449,420) | (699,117) |
Net Income | (298,329) | (334,620) | (443,286) | (704,471) |
Total Assets | 987,368 | 1,036,295 | 1,220,140 | 1,609,956 |
Total Debt | 83,682 | 15,151 | 20,393 | 15,540 |
Zai Lab Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Zai Lab Comparisons
Industry
Financing
Details
Zai Lab Competitors (41)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Alphamab Oncology | Formerly VC-backed | Suzhou, China | ||||
Xenetic Bioscience | Corporation | Framingham, MA | ||||
Sutro Biopharma | Formerly VC-backed | South San Francisco, CA | ||||
Dicerna Pharmaceuticals | Formerly VC-backed | Lexington, MA | ||||
BeiGene | Formerly PE-Backed | Cambridge, MA |
Zai Lab Patents
Zai Lab Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2022400921-A1 | Ccr8 antigen binding unit and uses thereof | Pending | 02-Dec-2021 | ||
CA-3239784-A1 | Ccr8 antigen binding unit and uses thereof | Pending | 02-Dec-2021 | ||
EP-4441098-A1 | Ccr8 antigen binding unit and uses thereof | Pending | 02-Dec-2021 | ||
EP-4342899-A1 | Salt form and crystal form of heterocyclic substituted purinone derivative | Inactive | 19-May-2021 | ||
US-20240254145-A1 | Salt form and crystal form of heterocyclic substituted purinone derivative | Pending | 19-May-2021 | C07D519/00 |
Zai Lab Signals
Zai Lab Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Zai Lab Investments (2)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Jing Medicine Technology | 05-Dec-2017 | Drug Discovery | |||
Caidya | 01-Dec-2016 | Early Stage VC | Laboratory Services (Healthcare) |
Zai Lab ESG
Risk Overview
Risk Rating
Updated May, 31, 2024
25.59 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 16,009
Rank
Percentile
Pharmaceuticals
Industry
of 909
Rank
Percentile
Biotechnology
Subindustry
of 404
Rank
Percentile
Zai Lab FAQs
-
When was Zai Lab founded?
Zai Lab was founded in 2014.
-
Where is Zai Lab headquartered?
Zai Lab is headquartered in Shanghai, China.
-
What is the size of Zai Lab?
Zai Lab has 2,175 total employees.
-
What industry is Zai Lab in?
Zai Lab’s primary industry is Biotechnology.
-
Is Zai Lab a private or public company?
Zai Lab is a Public company.
-
What is Zai Lab’s stock symbol?
The ticker symbol for Zai Lab is 09688.
-
What is the current stock price of Zai Lab?
As of 04-Nov-2024 the stock price of Zai Lab is $3.09.
-
What is the current market cap of Zai Lab?
The current market capitalization of Zai Lab is $3.07B.
-
What is Zai Lab’s current revenue?
The trailing twelve month revenue for Zai Lab is $323M.
-
Who are Zai Lab’s competitors?
Alphamab Oncology, Xenetic Bioscience, Sutro Biopharma, Dicerna Pharmaceuticals, and BeiGene are some of the 41 competitors of Zai Lab.
-
What is Zai Lab’s annual earnings per share (EPS)?
Zai Lab’s EPS for 12 months was -$0.31.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »